General

HLA codes for cell-surface glycoproteins that present antigens to T cells for protection of the host against peptide antigens emanating from non-self proteins. There are 2 HLA classes (I and II), each of which comprises 3 classical genes: A, B, C (Class I) and DPB1, DQB1, DRB1 (Class II). Each gene codes for a number of specific proteins. In the current 2-field notation, an HLA molecule is denoted by a string of 3 parts comprising the gene, the allele group, and the protein sequence coded by a specific allele. For example, HLA-A*11:15 denotes a unique protein (amino acid sequence) coded by the variant A*15:11 of gene A and allele group 15 of HLA Class I. A given gene codes for many allele groups, and each allele group codes for many different unique proteins, so that there exists a very large number of HLA-coded proteins [4].

HLA-I molecules are expressed in all nucleated cells and bind peptides coming from partial degradation of endogenous proteins (e.g., rapidly degraded self proteins, proteins of pathogens, tumor proteins, etc.) in the proteasome. By contrast, HLA-II molecules are typically expressed in the professional antigen-presenting cells (macrophages, dendritic, and B cells), but also in other cell types [5], including cancer cells [6–8]. HLA-II molecules bind peptides coming from partial degradation of exogenous proteins (internalized by pinocytosis and/or phagocytosis) in the lysosomal system. In addition, to some extent, peptides from proteins from either source (endogenous, exogenous) are made available to HLA-I or HLA-II molecules via the cross-presentation system [9]. Detailed reviews of HLA function and antigen processing and presentation can be found elsewhere [10–12].

Peptide binding and presentation

HLA-I molecules typically bind to peptides of 8–10 amino acid length (mostly 9-mers), whereas HLA-II molecules typically bind peptides of 13–18 amino acid length (mostly 15-mers). HLA molecules of both classes possess very high specificity and degeneracy [13, 14]. With respect to the former, a specific HLA molecule can bind with high affinity to only a few non-self antigens among a large number available, and can distinguish peptide antigens by even single amino acid substitutions. And with respect to the latter, a particular HLA molecule can bind a large number of peptides.

HLA-I and HLA-II molecules are unstable without a bound peptide and very stable when bound to a peptide with high affinity. In fact, the degree of stability is directly related to the strength of binding affinity. In the absence of a suitable peptide, HLA-I molecules are bound with low affinity to self peptides [15]. When a high-affinity peptide appears, the self peptide is replaced by it, conferring stability and paving the way for the peptide-HLA-I (pHLA-I) complex to move to the cell surface and present its peptide to T lymphocytes (T cells) that express the CD8 coreceptor (CD8+ T cells). Similarly, HLA-II molecules are also unstable without a bound peptide. In the absence of a high-affinity peptide, they are loosely bound to a local peptide, invariant chain (Ii) [16]. When a high-affinity peptide appears, it replaces Ii, the pHLA-II molecule thus formed is very stable and moves to the surface to present its peptide to T cells that express the CD4 coreceptor (CD4+ T cells). The stability of the pHLA-I and pHLA-II complexes is very important because it determines the time for which bound peptides can be presented to T cells: the longer they are presented, the higher the probability of attracting a T cell and the higher the number of T cells activated, amounting to a higher level of T cell activation.

Recent advances

Several advances in antigen processing and presentation have been made in recent years in diverse fields, including imaging of the pHLA complex [17], origin of peptides presented to HLA molecules [18], peptide transport and presentation [19], and pHLA dissemination by extracellular vesicles (EV) [20], among others. We review these advances briefly below.

CD8+ and CD4+ T lymphocytes

Peptides presented by the HLA-I and HLA-II molecules bind to the T cell receptor (TCR). Although the same generic notation (TCR) is used for both HLA molecules, the biophysics are different in the two cases, since two different, T cell specific, coreceptors are involved, namely CD8 for the pHLA-I specific CD8+ T cells and CD4 for the pHLA-II specific CD4+ T cells. Both coreceptors increase the stability of the pHLA complex and facilitate the ultimate activation of the T cell for an effective discharge of their effector actions described below. The peptide-TCR binding is characterized by very high specificity, sensitivity, and degeneracy. With respect to specificity, even a single amino acid residue substitution in the peptide can make a big difference in the probability of its binding to TCR, for both pHLA-I and pHLA-II molecules. With respect to sensitivity, a CD8+ T cell can be activated by a single pHLA-I complex [43], and a CD4+ T cell can be activated by a single pHLA-II complex [44]. And with respect to degeneracy, a single TCR of a CD8+ or CD4+ cell can be engaged by many pHLA complexes.

The main function of CD8+ T cells is the elimination of the cell that contains the peptide (antigen) presented by the pHLA-I complex. This is achieved by (a) direct cytotoxicity via the perforin-granzyme and Fas/FasL pathways leading to cell death (apoptosis), (b) the production and secretion of various cytokines enhancing the elimination and clearance of the target cell, mainly interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α), and (c) other mechanisms (e.g., bystander killing, pyroptosis, ferroptosis).

The activation of CD4+ T cells promotes and facilitates the elimination of non-self target cells by various mechanisms, including (a) the initiation of the production of antibodies by B cells against the presented peptide (and hence its associated protein), (b) enhancement of the function of cytotoxic CD8+ T cells, (c) production and secretion of various cytokines (e.g., IFN-γ) recruiting and enhancing the function of other cells (e.g., macrophages) aiding in the elimination and clearance of the target cell, and (d) direct cytotoxicity.

Following exposure to, and activation by, suitable antigens presented by pHLA-I and pHLA-II complexes, subsets of both CD8+ and CD4+ T cells differentiate into “memory cells” that react fast and effectively when those non-self antigens (e.g., from pathogens) are encountered in the future. Memory T cells and antibodies provide a timely, effective, and efficient response to eliminate previously presented non-self antigens (mostly viruses) when they reappear in the future.

HLA in cancer: immunoevasion

In cancer, HLA function is commonly suppressed, resulting in “immunoevasion”. Suppression of HLA-I expression has been well documented in various cancers due to various reasons [45–51]. In addition to HLA-I suppression, the function of antitumor cytolytic CD8+ T cells (the activation target of pHLA-I) is also suppressed [52]. The overall result of HLA-I suppression and CD8+ T cell exhaustion is promotion of tumor growth. Cytolytic T cell antitumor activity can be partially restored by immune checkpoint inhibitors (ICIs) therapy [53], but HLA-I suppression due to genetic alterations cannot be restored. Finally, it should be noted that HLA-I/CD8+ T cell dysfunction would adversely affect an otherwise positive outcome of the peptide-based cancer vaccines (discussed below), a therapy that would profit from a concomitant ICI therapy, as has been observed [54].

As mentioned above, HLA-II molecules are normally expressed mainly in professional antigen-presenting cells, but they have also been detected in other tissues [5] and cancer cells [6–8]. Alterations in the expression of HLA-II molecules in cancer cells have been observed in various tumors, intensities, and types affecting different stages in the biosynthesis of HLA-II molecules and their regulation [55–57]. Overall therapeutic effects have been associated with HLA-II expression in various cancers, especially with an enhanced effect of concomitant ICI treatment [8, 58–62].

Tumor antigens

Tumor antigens can be classified as tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs) [63]. TAAs are preferentially found or are overexpressed in tumors but may also be present in other cells; they include differentiation antigens and cancer germline antigens/cancer testis antigens (CTAs). CTAs are ideal targets for immunotherapy; they are highly immunogenic and, while overly expressed in various tumors, their expression in normal tissue is limited to the testis and placenta, which are immunologically privileged, thus reducing the likelihood of adverse autoimmune responses [64, 65]. Indeed, CTAs such as melanoma antigen gene (MAGE) and New York esophageal squamous cell carcinoma oncoprotein 1 (NY-ESO-1) proteins have been the targets of numerous immunotherapy trials [66, 67]. Human epidermal growth factor receptor 2 (HER2), a protein associated with the rapid growth of breast cancer, is another TAA for which targeted immunotherapies have been particularly effective, albeit with high rates of relapse or disease progression [68]. In contrast to TAAs, which are expressed on normal tissues, TSAs are uniquely found on tumor cells. TSAs include mutated proteins commonly referred to as neoantigens and viral antigens such as human papilloma virus (HPV), Epstein-Barr virus (EBV), and human endogenous retroviruses (HERVs) (e.g., viral antigens, neoantigens) [63]. Because they are not expressed in normal tissues [69] and escape negative selection as non-self antigens [70], TSAs—particularly, neoantigens [71–73]—have increasingly become immunotherapy targets. The meteoric growth of interest in neoantigen-based cancer immunotherapy studies has led to promising advancements in personalized cancer immunotherapy [74, 75] and identified limitations of neoantigen-based immunotherapeutic approaches, including high neoantigen heterogeneity even within a given tumor [49] with relatively few neoantigens that are highly immunogenic [72, 76–80], potentially contributing to immune escape. Ongoing efforts are aimed at the identification of immunogenic epitopes and optimizing strategies to target both TAAs and TSAs via various types of immunotherapies [74, 80, 81].

In general, cancer immunotherapies share a common goal of enhancing the immune system’s anticancer activity, albeit they operate via different strategies. Standard immunotherapeutic strategies, including monoclonal antibodies (mAbs), T cell therapies, and cancer vaccines, reviewed elsewhere [82, 83], are summarized below.

mAbs

Briefly, mAbs are antibodies that are manufactured to bind to specific target antigens (e.g., HER2, immune checkpoints), causing tumor cell death by various effector mechanisms [68, 84]. Dozens of mAbs are FDA-approved and used clinically to treat cancer [83]. ICIs, a specific type of mAbs that bind with checkpoint proteins that would otherwise suppress the ability of T cells to destroy a tumor, are the first or second line of treatment for several cancers [82, 85]. Treatment with mAbs has been shown to significantly improve survival [82, 84, 86, 87]; however, serious side effects, resistance to treatment, and cancer re-occurrence are common limitations of mAbs [85, 88–90].

T cell therapies

T cell therapies involve collecting and manipulating a patient’s T cells to more effectively recognize and kill cancer cells. T cell therapies for cancer include infusion of tumor-infiltrating lymphocytes (TILs) obtained from a resected tumor and grown in large quantities ex vivo or infusion of T cells that are genetically engineered to express either a synthetic chimeric antigen receptor (CAR) that recognizes cell-surface tumor antigens or a T-cell receptor (TCR-T therapy) that recognizes intracellular tumor antigens [67]. Serious adverse effects, poor persistence, cancer cell resistance, and prohibitive costs limit the use of CAR-T cell therapies primarily to hematological cancers [67, 91, 92]. Similarly, toxicity and cross-reactivity with normal tissues are a concern for TCR-T [93], although it is relatively safer than CAR-T because of its MHC restriction [94] and has proven at least somewhat beneficial for synovial sarcoma and melanoma (targeting CTAs) and for HPV-associated cancers (targeting HPV antigens) [67]. As far as safety, TIL therapy has the advantage as it relies on a patient’s natural T cells [83]; however, costly and time-consuming production limits their use to the second line of therapy or adjunctive to ICIs [95].

Tumor antigen-based vaccines

Therapeutic cancer vaccines stimulate T cell responses to target TAAs or TSAs via various platforms, including dendritic cells (DCs), viruses, peptides, and nucleic acids, as reviewed elsewhere [66, 96–99]. Cancer vaccines are safe, and several have been approved for use [100–102]. In recent years, peptide-based and nucleic acid-based vaccines have attracted substantial attention [103–106]. Peptide-based vaccines present tumor antigen epitopes to antigen-presenting cells, where the epitopes bind with MHC molecules and are presented to T cells to facilitate elimination of tumor cells. Although an appealing and promising approach to cancer immunotherapy, peptide-based cancer vaccine trials to date have demonstrated limited efficacy [104]; however, identification of optimal antigens to enhance immune response against tumor cells is an active area of investigation and a strategy that is ripe for personalized interventions [98, 104, 105]. The recent development of nucleic acid-based vaccines has ushered in new approaches for cancer treatment. The basis of nucleic acid-based vaccines for cancer rests on delivering genetic instructions for the production of cancer antigens, which once manufactured, are bound to HLA molecules, signaling cell destruction [105, 106]. As with peptide-based vaccines, selection of immunogenic antigens is a crucial factor in the effectiveness of nucleic acid-based vaccines. Immunogenicity, at least in part, is determined by individual variation in HLA; thus, individual HLA composition is at the very core of personalized cancer immunotherapy. In fact, to achieve the goal of eliminating a cancer (or infected) cell, the single necessary and sufficient step for T cell activation is the formation of a stable pHLA complex, a condition that rests on the specific HLA alleles carried by the patient. Advances in bioinformatics and sequencing permit the prediction of immunogenicity that can be leveraged to identify optimal antigens.

HLA-based vaccines

As reviewed above, a major effort in tumor elimination is HLA-dependent, in that immunogenic peptides of TAA are delivered to the tumor, systemically or via DC pulsing, to maximize their binding to HLA-I molecules, leading to activation of CD8+ T cells and ensuing killing of tumor cells by the mechanisms mentioned above. This approach is usually more effective with concurrent administration of ICI treatment. The essential requirement for a successful outcome is that the peptides administered bind with high affinity to at least some of the six HLA-I molecules that a given patient carries. In most studies, the selection of the administered peptides is based on general considerations of their antigenicity but, as discussed above, the key lies in the strength of binding affinity of these peptides to the specific HLA-I molecules of the patient, a point taken seriously into account in some studies [107, 108].

A complementary alternative would be to enable the synthesis in the tumor cells of HLA-I molecules with predicted high-affinity binding to TAA epitopes [109]. In a recent study, we identified 9 HLA-I molecules with highly immunogenic binding to epitopes from 11 melanoma-associated antigens [110]. Such molecules could be synthesized from their mRNA blueprint and injected intratumorally. The same approach can be applied with respect to HLA-II molecules. In this case, the engagement of CD4+ T cells would have the dual advantage of (a) enhancing the cytolytic action of CD8+ T cells and (b) leading to the production of antitumor antibodies by B cells. To our knowledge, these approaches have not been tried yet.

Tumor rejection by antibodies against non-tumor antigens

All current cancer immunotherapies are directed against cancer cells. Here, we propose a new kind of immunotherapy that is also directed against the tumor itself, but through antibodies against non-tumor antigens. Such antigens may already exist naturally in the body (e.g., the ABH blood group antigens), or they can be synthesized by the tumor cells by injecting into the tumor relevant mRNA blueprints of these antigens (e.g., HLA molecules). In both cases, the destruction of the tumor is expected to resemble the rejection of a transplanted organ to an antigen-incompatible recipient. For example, without special pre-surgery preparation, organ transplants between ABO or HLA incompatible individuals are rejected at various times, from minutes or hours (“hyperacute rejection”, typically due to ABO incompatibility) to weeks or months (“acute rejection”, typically due to HLA incompatibility). In what follows, we discuss this approach, namely, treating a tumor as a foreign organ to be rejected.

Tumor rejection due to incompatible HLA

In the case of organ transplantation, HLA proteins of the donor, expressed in the organ transplant (e.g., kidney), are highly immunogenic for a recipient that lacks them (“HLA incompatibility”). They are treated by the transplant recipient as non-self antigens, and, as such, are targeted for elimination by the usual immune mechanisms implemented by CD8+ and CD4+ T cells, resulting in destruction of the tissue that contains them and thus rejection of the transplant. In fact, HLA incompatibility accounts for most organ rejections [111, 112], hence the effort to match the HLA makeup of the recipient to that of the donor. Unfortunately, only monozygotic twins have a perfect match, and, otherwise, the closer (i.e., less incompatible) the HLAs of the donor and recipient are, the better the chance of transplant retention [111, 112].

By contrast, in the case of cancer, the objective is just the opposite, namely, to reject the tumor. To that end, highly immunogenic proteins need to be introduced into the tumor, and HLA proteins fulfill that requirement, since they are known to be highly immunogenic. A realistic scenario for such an HLA-based approach for solid tumor rejection is outlined in Figures 1 and 2. In that treatment, HLA molecules, incompatible with those of the patient, would be introduced into the tumor (e.g., using their mRNA blueprint), essentially transforming the tumor to an incompatible transplant and leading to its destruction/rejection by the same mechanisms involved in rejecting an HLA-incompatible transplant. Proteins of the heavy α chain of HLA-I molecules would be ideal to use due to their known high immunogenicity, medium size (~365 amino acids), and available sequence(s); mRNA of several of them could be injected into the tumor. Given that the only requirement would be that they would differ (i.e., be incompatible) with regard to the HLA-I molecules of the patient, mRNAs of a large number of such proteins could be made, stored, and used without any delay in the case of a particular patient, a promising feature.

Display full size

Figure 1. Outline of tumor rejection therapy based on HLA incompatibility. HLA: human leukocyte antigen.

Display full size

Figure 2. Features of tumor rejection therapy based on HLA incompatibility. HLA: human leukocyte antigen.

Now, although rejection of an HLA-incompatible transplanted organ is predictable and certain (“acute rejection”) without immunosuppressive treatment, in the case of a solid tumor, the outcome would depend on the status of the immune function/dysfunction at the tumor’s microenvironment (immunoevasion). For example, if the expression of the HLA-I/HLA-II molecules is suppressed or impaired, epitopes of the incompatible HLA molecule(s) inserted in the tumor (via their mRNA) may not be adequately presented to CD8+ and CD4+ T cells, the function of which might be impaired as well. Therefore, the outcome of this treatment could be quite variable and would depend on the extent to which CD8+/CD4+ T cell function has been restored by concomitant immunotherapy, such as ICI therapy.

With respect to potential adverse effects, it is possible that antibodies against the incompatible HLA molecules may attack other proteins in the body, mostly due to shared epitopes between the HLA inserted in the tumor and other body proteins (molecular mimicry). This occurs infrequently in solid organ transplantation. In fact, it was estimated that HLA-I proteins share < 0.8% epitopes with proteins of the human proteome [113]. These, and possibly other, considerations lead us to propose an approach that would involve direct antigen-antibody reaction against universal, preexisting antigens in the tumor, without the need to engage the immune system of the patient. This approach involves the blood group ABH antigens and the antibodies against them, as discussed next.

Tumor rejection due to incompatible ABH blood group antigens

Solid tumor rejection therapy

Unlike the case of transplantation, where every effort is expended to prevent organ rejection [111, 112, 118], in the case of a solid tumor, the objective is the opposite, namely, tumor rejection. Fortunately, with this approach, the antibodies are preformed and do not need to be produced, hence the condition of the immune system in the tumor microenvironment is irrelevant. Here, the main issues concern the items to be delivered and the method and rate of delivery. The method and features of this therapy are outlined in Figures 3 and 4, respectively. With respect to the antibodies to be delivered intratumorally, there are 4 separate cases, depending on the blood type of the cancer patient. (1) For patients with type A, natural, preformed anti-A antibodies would be delivered; such antibodies exist commercially (for use in research) in a purified form or as serum from a type B donor. (2) For patients with type B, anti-B antibodies would be used. (3) For patients with type AB, either anti-A or anti-B (or a combination of both) would be used. Finally, (4) for patients of type O, anti-H antibodies would be used.

Display full size

Figure 3. Outline of tumor rejection therapy using intra-tumor injection of anti-A/B/H antibodies. See text for details.

Display full size

Figure 4. Features of tumor rejection therapy using intra-tumor injection of anti-ABH blood group antibodies.

In the case of an accessible solid tumor, these antibodies can be injected intratumorally. Since this treatment can have serious adverse effects if the antibodies/antigens spread outside the tumor in substantial amounts, special care needs to be taken to inject them into the tumor precisely and at a very slow rate. Since they are very potent and act immediately, a slow infusion over a period of time is most likely to be effective; it does not have to be continuous, but for example, daily injections of small amounts would be expected to shrink the tumor gradually. Since tumors are frequently well vascularized, the antibodies should be very effective in destroying the tumor, little by little. In addition, since endothelial cells of lymphatic vessels in the tumor also express the ABH antigens, the injected anti-ABH antibodies will also destroy the lymph vessels of the tumor [119], thus limiting the spread of the tumor to adjacent lymph nodes. The main potential adverse effect is hemolysis and/or thrombosis, hence close monitoring would be essential.

Finally, attention has been drawn to developing cancer treatment based on AB incompatibility [120, 121], and results of experiments using a lentivirus to introduce the A antigen in solid breast and colorectal tumors in mice expressing anti-A antibodies have been encouraging. This approach is much more involved than the simple infusion of antibodies discussed above, but documents the positive result in solid tumor reduction effected by the concomitant presence in the tumor of the A antigen and its anti-A antibody.